Shares of Horizon Pharma PLC (NASDAQ:HZNP) have been assigned an average rating of “Buy” from the seventeen analysts that are covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $19.46.

A number of research analysts have recently issued reports on the stock. Piper Jaffray Companies set a $18.00 price target on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a research report on Monday, August 7th. Cowen and Company set a $20.00 price target on shares of Horizon Pharma PLC and gave the stock an “outperform” rating in a research report on Tuesday, May 9th. BidaskClub downgraded shares of Horizon Pharma PLC from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Mizuho downgraded shares of Horizon Pharma PLC from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $22.00 to $10.00 in a research report on Tuesday, May 9th. Finally, Jefferies Group LLC set a $14.00 price target on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a research report on Tuesday, May 9th.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HZNP. BlackRock Inc. increased its position in Horizon Pharma PLC by 1.8% in the second quarter. BlackRock Inc. now owns 13,500,226 shares of the biopharmaceutical company’s stock worth $160,247,000 after buying an additional 239,014 shares during the last quarter. Vanguard Group Inc. increased its position in Horizon Pharma PLC by 1.8% in the second quarter. Vanguard Group Inc. now owns 12,982,718 shares of the biopharmaceutical company’s stock worth $154,105,000 after buying an additional 233,443 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Horizon Pharma PLC by 119.4% in the second quarter. Dimensional Fund Advisors LP now owns 6,265,608 shares of the biopharmaceutical company’s stock worth $74,373,000 after buying an additional 3,409,411 shares during the last quarter. State Street Corp increased its position in Horizon Pharma PLC by 12.0% in the second quarter. State Street Corp now owns 4,906,307 shares of the biopharmaceutical company’s stock worth $58,241,000 after buying an additional 524,187 shares during the last quarter. Finally, Janus Capital Management LLC increased its position in Horizon Pharma PLC by 19.4% in the first quarter. Janus Capital Management LLC now owns 4,409,717 shares of the biopharmaceutical company’s stock worth $65,173,000 after buying an additional 717,643 shares during the last quarter. Institutional investors own 83.75% of the company’s stock.

Shares of Horizon Pharma PLC (NASDAQ:HZNP) traded down 1.57% during trading on Tuesday, reaching $13.14. 2,456,773 shares of the company’s stock were exchanged. Horizon Pharma PLC has a 52-week low of $9.45 and a 52-week high of $21.98. The company’s market capitalization is $2.15 billion. The company has a 50 day moving average price of $12.66 and a 200-day moving average price of $13.40.

Horizon Pharma PLC (NASDAQ:HZNP) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.29. The firm had revenue of $289.51 million for the quarter, compared to the consensus estimate of $237.01 million. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. The company’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.56 EPS. On average, equities analysts forecast that Horizon Pharma PLC will post $1.08 earnings per share for the current year.

Horizon Pharma PLC declared that its board has initiated a share buyback plan on Monday, May 8th that authorizes the company to buyback 1,000% of outstanding shares. This buyback authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Stock buyback plans are often a sign that the company’s leadership believes its shares are undervalued.

COPYRIGHT VIOLATION WARNING: “Analysts Set Horizon Pharma PLC (HZNP) PT at $19.46” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://theolympiareport.com/2017/08/27/analysts-set-horizon-pharma-plc-hznp-pt-at-19-46.html.

About Horizon Pharma PLC

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Analyst Recommendations for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.